The emerging relationship between metabolism and DNA repair

References

• Lombard DB, Chua KF, Mostoslavsky R, et al. DNA repair, genome stability, and aging. Cell. 2005;120(4):497–512.
   PubMed Web of Science ®Google Scholar
• Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer. 2016;16(1):35–42.
   PubMed Web of Science ®Google Scholar
• Bouwman P, Jonkers J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012;12(9):587–598.
   PubMed Web of Science ®Google Scholar
• Ghosal G, Chen J. DNA damage tolerance: a double-edged sword guarding the genome. Transl Cancer Res. 2013;2(3):107–129.
   PubMed Web of Science ®Google Scholar
• Wolters S, Schumacher B. Genome maintenance and transcription integrity in aging and disease. Front Genet. 2013;4:19.
   PubMedGoogle Scholar
• Cassim S, Vučetić M, Ždralević M, et al. Warburg and Beyond: the Power of Mitochondrial Metabolism to Collaborate or Replace Fermentative Glycolysis in Cancer.Cancers (Basel). 2020;12:5.
   Google Scholar
• Parks SK, Mueller-Klieser W, Pouysségur J Lactate and Acidity in the Cancer Microenvironment. Annual Review of Cancer Biology; 2020. p. 141–58.
   Google Scholar
• Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.
   PubMed Web of Science ®Google Scholar
• Cassim S, Raymond VA, Dehbidi-Assadzadeh L, et al. Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment. Cell Cycle. 2018;17(7):903–916.
   PubMed Web of Science ®Google Scholar
• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95.
   PubMed Web of Science ®Google Scholar
• Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016;23(1):27–47.
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, et al. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14(2):113.
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2(5):e1600200.
   PubMed Web of Science ®Google Scholar
• Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014;39(8):347–354.
   PubMed Web of Science ®Google Scholar
• Rabinovich S, Adler L, Yizhak K, et al. Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature. 2015;527(7578):379–383.
   PubMed Web of Science ®Google Scholar
• Kim J, Hu Z, Cai L, et al. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature. 2017;546(7656):168–172.
   PubMed Web of Science ®Google Scholar
• Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24(10):R453–62.
   PubMed Web of Science ®Google Scholar
• Panieri E, Santoro MM. ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis. 2016;7(6):e2253.
   PubMedGoogle Scholar
• Cosentino C, Grieco D, Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. Embo J. 2011;30(3):546–555.
   PubMed Web of Science ®Google Scholar
• Aird KM, Worth AJ, Snyder NW, et al. ATM couples replication stress and metabolic reprogramming during cellular senescence. Cell Rep. 2015;11(6):893–901.
   PubMed Web of Science ®Google Scholar
• Canman CE, Lim DS, Cimprich KA, et al. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 1998;281(5383):1677–1679.
   PubMed Web of Science ®Google Scholar
• Kim ST, Lim DS, Canman CE, et al. Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem. 1999;274(53):37538–37543.
   PubMed Web of Science ®Google Scholar
• Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421(6922):499–506.
   PubMed Web of Science ®Google Scholar
• Schneider JG, Finck BN, Ren J, et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab. 2006;4(5):377–389.
   PubMed Web of Science ®Google Scholar
• Alexander A, Cai SL, Kim J, et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A. 2010;107(9):4153–4158.
   PubMed Web of Science ®Google Scholar
• Guo Z, Kozlov S, Lavin MF, et al. ATM activation by oxidative stress. Science. 2010;330(6003):517–521.
   PubMed Web of Science ®Google Scholar
• Eaton JS, Lin ZP, Sartorelli AC, et al. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. J Clin Invest. 2007;117(9):2723–2734.
   PubMed Web of Science ®Google Scholar
• Ambrose M, Goldstine JV, Gatti RA. Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells. Hum Mol Genet. 2007;16(18):2154–2164.
   PubMed Web of Science ®Google Scholar
• Valentin-Vega YA, Maclean KH, Tait-Mulder J, et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood. 2012;119(6):1490–1500.
   PubMed Web of Science ®Google Scholar
• Jain M, Brenner DA, Cui L, et al. Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes. Circ Res. 2003;93(2):e9–16.
   PubMed Web of Science ®Google Scholar
• Sun K, Tang S, Hou Y, et al. Oxidized ATM-mediated glycolysis enhancement in breast cancer-associated fibroblasts contributes to tumor invasion through lactate as metabolic coupling. EBioMedicine. 2019;41:370–383.
   PubMed Web of Science ®Google Scholar
• Hartley KO, Gell D, Smith GC, et al. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell. 1995;82(5):849–856.
   PubMed Web of Science ®Google Scholar
• Jackson SP. DNA-dependent protein kinase. Int J Biochem Cell Biol. 1997;29(7):935–938.
   PubMed Web of Science ®Google Scholar
• Wong RH, Chang I, Hudak CS, et al. A role of DNA-PK for the metabolic gene regulation in response to insulin. Cell. 2009;136(6):1056–1072.
   PubMed Web of Science ®Google Scholar
• Amatya PN, Kim HB, Park SJ, et al. A role of DNA-dependent protein kinase for the activation of AMP-activated protein kinase in response to glucose deprivation. Biochim Biophys Acta. 2012;1823(12):2099–2108.
   PubMed Web of Science ®Google Scholar
• Ruderman NB, Carling D, Prentki M, et al. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest. 2013;123(7):2764–2772.
   PubMed Web of Science ®Google Scholar
• Park SJ, Gavrilova O, Brown AL, et al. DNA-PK Promotes the Mitochondrial, Metabolic, and Physical Decline that Occurs During Aging. Cell Metab. 2017;25(5):1135–46.e7.
   PubMed Web of Science ®Google Scholar
• Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene. 1999;18(53):7644–7655.
   PubMed Web of Science ®Google Scholar
• Levine AJ, Hu W, The FZ. P53 pathway: what questions remain to be explored? Cell Death Differ. 2006;13(6):1027–1036.
   PubMed Web of Science ®Google Scholar
• Riley T, Sontag E, Chen P, et al. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9(5):402–412.
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–310.
   PubMed Web of Science ®Google Scholar
• Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004;64(7):2627–2633.
   PubMed Web of Science ®Google Scholar
• Bensaad K, Tsuruta A, Selak MA, et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006;126(1):107–120.
   PubMed Web of Science ®Google Scholar
• Bansal A, Simon MC. Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol. 2018;217(7):2291–2298.
   PubMed Web of Science ®Google Scholar
• Wu G, Fang YZ, Yang S, et al. Glutathione metabolism and its implications for health. J Nutr. 2004;134(3):489–492.
   PubMed Web of Science ®Google Scholar
• Franklin DA, He Y, Leslie PL, et al. p53 coordinates DNA repair with nucleotide synthesis by suppressing PFKFB3 expression and promoting the pentose phosphate pathway. Sci Rep. 2016;6:38067.
   PubMed Web of Science ®Google Scholar
• Jiang P, Du W, Wang X, et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol. 2011;13(3):310–316.
   PubMed Web of Science ®Google Scholar
• Matoba S, Kang JG, Patino WD, et al. p53 regulates mitochondrial respiration. Science. 2006;312(5780):1650–1653.
   PubMed Web of Science ®Google Scholar
• Papadopoulou LC, Sue CM, Davidson MM, et al. Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. Nat Genet. 1999;23(3):333–337.
   PubMed Web of Science ®Google Scholar
• Wang S, Peng Z, Yang L, et al. KRAB-type zinc-finger proteins PITA and PISA specifically regulate p53-dependent glycolysis and mitochondrial respiration. Cell Res. 2018;28(5):572–592.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Tanaka T, Poyurovsky MV, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A. 2010;107(16):7461–7466.
   PubMed Web of Science ®Google Scholar
• Maddocks OD, Berkers CR, Mason SM, et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2013;493(7433):542–546.
   PubMed Web of Science ®Google Scholar
• Tajan M, Hock AK, Blagih J, et al. A Role for p53 in the Adaptation to Glutamine Starvation through the Expression of SLC1A3. Cell Metab. 2018;28(5):721–36.e6.
   PubMed Web of Science ®Google Scholar
• Kim J, Yu L, Chen W, et al. Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation. Cancer Cell. 2019;35(2):191–203.e8.
   PubMed Web of Science ®Google Scholar
• Krokan HE, Bjørås M. Base excision repair. Cold Spring Harb Perspect Biol. 2013;5(4):a012583–a.
   PubMed Web of Science ®Google Scholar
• Sultana R, Abdel-Fatah T, Abbotts R, et al. Targeting XRCC1 Deficiency in Breast Cancer for Personalized Therapy. Cancer Res. 2013;73(5):1621.
   PubMed Web of Science ®Google Scholar
• Markkanen E, Fischer R, Ledentcova M, et al. Cells deficient in base-excision repair reveal cancer hallmarks originating from adjustments to genetic instability. Nucleic Acids Res. 2015;43(7):3667–3679.
   PubMed Web of Science ®Google Scholar
• Rashid S, Freitas MO, Cucchi D, et al. MLH1 deficiency leads to deregulated mitochondrial metabolism. Cell Death Dis. 2019;10(11):795.
   PubMedGoogle Scholar
• Murata MM, Kong X, Moncada E, et al. NAD+ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival. Mol Biol Cell. 2019;30(20):2584–2597.
   PubMed Web of Science ®Google Scholar
• Bai P, Cantó C, Oudart H, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 2011;13(4):461–468.
   PubMed Web of Science ®Google Scholar
• Yu J, Auwerx J. The role of sirtuins in the control of metabolic homeostasis. Ann N Y Acad Sci. 2009;1173(1):E10–E9.
   PubMedGoogle Scholar
• Ke Y, Wang C, Zhang J, et al. The Role of PARPs in Inflammation-and Metabolic-Related Diseases: molecular Mechanisms and Beyond. Cells. 2019;8(9):1047.
   PubMed Web of Science ®Google Scholar
• Bhute VJ, Palecek SP. Metabolic responses induced by DNA damage and poly (ADP-ribose) polymerase (PARP) inhibition in MCF-7 cells. Metabolomics. 2015;11(6):1779–1791.
   PubMed Web of Science ®Google Scholar
• Masson M, Niedergang C, Schreiber V, et al. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol. 1998;18(6):3563–3571.
   PubMed Web of Science ®Google Scholar
• Horton JK, Stefanick DF, Gassman NR, et al. Preventing oxidation of cellular XRCC1 affects PARP-mediated DNA damage responses. DNA Repair (Amst). 2013;12(9):774–785.
   PubMed Web of Science ®Google Scholar
• Spivak G. Nucleotide excision repair in humans. DNA Repair (Amst). 2015;36:13–18.
   PubMed Web of Science ®Google Scholar
• Milanese C, Bombardieri CR, Sepe S, et al. DNA damage and transcription stress cause ATP-mediated redesign of metabolism and potentiation of anti-oxidant buffering. Nat Commun. 2019;10(1):4887.
   PubMedGoogle Scholar
• Li G-M. Mechanisms and functions of DNA mismatch repair. Cell Res. 2008;18(1):85–98.
   PubMed Web of Science ®Google Scholar
• Brierley DJ, Martin SA.Oxidative Stress and the DNA Mismatch Repair Pathway. Antioxid Redox Signal. 2013;18(18):2420–2428.
   PubMed Web of Science ®Google Scholar
• Russo MT, De Luca G, Degan P, et al. DNA repair strategies to combat the threat from 8-oxoguanine. Mutat Res. 2007;614(1):69–76.
   PubMed Web of Science ®Google Scholar
• Mishra M, Kowluru RA. Retinal Mitochondrial DNA Mismatch Repair in the Development of Diabetic Retinopathy, and Its Continued Progression After Termination of Hyperglycemia. Invest Ophthalmol Vis Sci. 2014;55(10):6960–6967.
   PubMed Web of Science ®Google Scholar
• Mason PA, Matheson EC, Hall AG, et al. Mismatch repair activity in mammalian mitochondria. Nucleic Acids Res. 2003;31(3):1052–1058.
   PubMed Web of Science ®Google Scholar
• Fontana GA, Gahlon HL. Mechanisms of replication and repair in mitochondrial DNA deletion formation. Nucleic Acids Res. 2020;48(20):11244–11258.
   PubMed Web of Science ®Google Scholar
• Martin SA, McCabe N, Mullarkey M, et al. DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1. Cancer Cell. 2010;17(3):235–248.
   PubMed Web of Science ®Google Scholar
• Martin SA, McCarthy A, Barber LJ, et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med. 2009;1(6–7):323–337.
   PubMed Web of Science ®Google Scholar
• Hewish M, Martin SA, Elliott R, et al. Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress. Br J Cancer. 2013;108(4):983–992.
   PubMed Web of Science ®Google Scholar
• Guillotin D, Austin P, Begum R, et al. Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA Mismatch Repair Deficient Cells. Clin Cancer Res. 2017;23(11):2880–2890.
   PubMed Web of Science ®Google Scholar
• Martin SA, Hewish M, Sims D, et al. Parallel High-Throughput RNA Interference Screens Identify PINK1 as a Potential Therapeutic Target for the Treatment of DNA Mismatch Repair–Deficient Cancers. Cancer Res. 2011;71(5):1836–1848.
   PubMed Web of Science ®Google Scholar
• Mootha VK, Bunkenborg J, Olsen JV, et al. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell. 2003;115(5):629–640.
   PubMed Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71.
   PubMed Web of Science ®Google Scholar
• Couch FJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum Mutat. 1996;8(1):8–18.
   Google Scholar
• Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol. 2003;15(3):345–350.
   PubMed Web of Science ®Google Scholar
• Magnard C, Bachelier R, Vincent A, et al. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene. 2002;21(44):6729–6739.
   PubMed Web of Science ®Google Scholar
• Moreau K, Dizin E, Ray H, et al. BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem. 2006;281(6):3172–3181.
   PubMed Web of Science ®Google Scholar
• Privat M, Radosevic-Robin N, Aubel C, et al. BRCA1 induces major energetic metabolism reprogramming in breast cancer cells. PLoS One. 2014;9(7):e102438.
   PubMed Web of Science ®Google Scholar
• Concolino A, Olivo E, Tammè L, et al. Proteomics Analysis to Assess the Role of Mitochondria in BRCA1-Mediated Breast Tumorigenesis. Proteomes. 2018;6:2.
   Web of Science ®Google Scholar
• Kanakkanthara A, Kurmi K, Ekstrom TL, et al. BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. Cancer Res. 2019;79(23):5920–5929.
   PubMed Web of Science ®Google Scholar
• Singh KK, Shukla PC, Yanagawa B, et al. Regulating cardiac energy metabolism and bioenergetics by targeting the DNA damage repair protein BRCA1. J Thorac Cardiovasc Surg. 2013;146(3):702–709.
   PubMed Web of Science ®Google Scholar
• Kc J, Ek G, Norrbom J, et al. BRCA1 is a novel regulator of metabolic function in skeletal muscle. J Lipid Res. 2014;55(4):668–680.
   PubMed Web of Science ®Google Scholar
• Kc J, Tarpey MD, Ap V, et al. Induced Cre-mediated knockdown of Brca1 in skeletal muscle reduces mitochondrial respiration and prevents glucose intolerance in adult mice on a high-fat diet. Faseb J. 2018;32(6):3070–3084.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Kim HJ, Rih JK, et al. BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression. J Biol Chem. 2006;281(19):13047–13056.
   PubMed Web of Science ®Google Scholar
• Xiang T, Ohashi A, Huang Y, et al. Negative Regulation of AKT Activation by BRCA1. Cancer Res. 2008;68(24):10040–10044.
   PubMed Web of Science ®Google Scholar
• Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci U S A. 1997;94(2):514–519.
   PubMed Web of Science ®Google Scholar
• Druzhyna NM, Wilson GL, LeDoux SP. Mitochondrial DNA repair in aging and disease. Mech Ageing Dev. 2008;129(7–8):383–390.
   PubMed Web of Science ®Google Scholar
• Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12(10):685–698.
   PubMed Web of Science ®Google Scholar
• Boesch P, Weber-Lotfi F, Ibrahim N, et al. DNA repair in organelles: pathways, organization, regulation, relevance in disease and aging. Biochim Biophys Acta. 2011;1813(1):186–200.
   PubMed Web of Science ®Google Scholar
• Liu P, Demple B. DNA repair in mammalian mitochondria: much more than we thought? Environ Mol Mutagen. 2010;51(5):417–426.
   PubMed Web of Science ®Google Scholar
• Yang JL, Weissman L, Bohr VA, et al. Mitochondrial DNA damage and repair in neurodegenerative disorders. DNA Repair (Amst). 2008;7(7):1110–1120.
   PubMed Web of Science ®Google Scholar
• Prakash A, Base Excision DS. Repair in the Mitochondria. J Cell Biochem. 2015;116(8):1490–1499.
   PubMed Web of Science ®Google Scholar
• Sharma P, Sampath SH. Mitochondrial DNA Integrity: role in Health and Disease. Cells. 2019;8(2):2.
   Web of Science ®Google Scholar
• Komakula SSB, Tumova J, Kumaraswamy D, et al. The DNA Repair Protein OGG1 Protects Against Obesity by Altering Mitochondrial Energetics in White Adipose Tissue. Sci Rep. 2018;8(1):14886. .
   PubMedGoogle Scholar
• Sykora P, Kanno S, Akbari M, et al. DNA Polymerase Beta Participates in Mitochondrial DNA Repair. Mol Cell Biol. 2017;37(16):16. .
   Web of Science ®Google Scholar
• Kazak L, Reyes A, Holt IJ. Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol. 2012;13(10):659–671.
   PubMed Web of Science ®Google Scholar
• Cassim S, Pouyssegur PJ. Tumor Microenvironment: a Metabolic Player that Shapes the Immune Response. Int J Mol Sci. 2019;21(1):1.
   Web of Science ®Google Scholar
• Coller HA. Is Cancer a Metabolic Disease? Am J Pathol. 2014;184(1):4–17.
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, et al. Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response. Cell Cycle. 2011;10(9):1499–1501.
   PubMed Web of Science ®Google Scholar
• Wheaton WW, Weinberg SE, Hamanaka RB, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014;3:e02242.
   PubMed Web of Science ®Google Scholar
• Molina JR, Sun Y, Protopopova M, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24(7):1036–1046. .
   PubMed Web of Science ®Google Scholar
• Á L, Hyroššová P, Figueras A, et al. Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors. EMBO Mol Med. 2020;12(6):e11217.
   PubMed Web of Science ®Google Scholar
• Jiang J, Chen Y, Dong T, et al. Polydatin inhibits hepatocellular carcinoma via the AKT/STAT3-FOXO1 signaling pathway. Oncol Lett. 2019;17(5):4505.
   PubMed Web of Science ®Google Scholar
• Mele L, La Noce M, Paino F, et al. Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation. J Exp Clin Cancer Res. 2019;38(1):160.
   PubMedGoogle Scholar
• Jang M, Kim SS, Lee J. Cancer cell metabolism: implications for therapeutic targets. Exp Mol Med. 2013;45(10):e45–e.
   PubMedGoogle Scholar
• Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019;150:104511.
   PubMed Web of Science ®Google Scholar
• Hoxhaj G, Manning BD. The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74–88.
   PubMed Web of Science ®Google Scholar
• André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929–1940.
   PubMed Web of Science ®Google Scholar
• Markham A. . Idelalisib: first Global Approval. Drugs. 2014;74(14):1701–1707.
   PubMed Web of Science ®Google Scholar
• Yang J, Nie J, Ma X, et al. PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18(1):26.
   PubMed Web of Science ®Google Scholar
• Anderson NM, Mucka P, Kern JG, et al. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018;9(2):216–237.
   PubMed Web of Science ®Google Scholar
• Chen M, Huang J. The expanded role of fatty acid metabolism in cancer: new aspects and targets. Precision Clin Med. 2019;2(3):183–191.
   PubMedGoogle Scholar
• Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122(1):4–22.
   PubMed Web of Science ®Google Scholar
• Punekar S, Cho DC. Novel Therapeutics Affecting Metabolic Pathways. Am Soc Clin Oncol Educ Book.2019 (39):e79–e87.
   Google Scholar
• Li E-Q, Zhao W, Zhang C, et al. Synthesis and anti-cancer activity of ND-646 and its derivatives as acetyl-CoA carboxylase 1 inhibitors. Eur J Pharm Sci. 2019;137:105010.
   PubMed Web of Science ®Google Scholar
• Svensson RU, Parker SJ, Eichner LJ, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med. 2016;22(10):1108–1119.
   PubMed Web of Science ®Google Scholar
• Kim YI. Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res. 2007;51(3):267–292.
   PubMed Web of Science ®Google Scholar
• Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007;26(1):153–181.
   PubMed Web of Science ®Google Scholar
• Krug LM, Azzoli CG, Kris MG, et al. 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer. Clin Cancer Res. 2003;9(6):2072–2078.
   PubMed Web of Science ®Google Scholar
• Jackman AL, Taylor GA, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res. 1991;51(20):5579–5586.
   PubMed Web of Science ®Google Scholar
• Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57(6):1116–1123.
   PubMed Web of Science ®Google Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–338.
   PubMed Web of Science ®Google Scholar
• Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22(4 Suppl 11):3–10.
   PubMed Web of Science ®Google Scholar
• Chen L, Pankiewicz KW. Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discovery Dev. 2007;10(4):403–412.
   PubMedGoogle Scholar
• Zou J, Han Z, Zhou L, et al. Elevated expression of IMPDH2 is associated with progression of kidney and bladder cancer. Med Oncol. 2015;32(1):373.
   PubMed Web of Science ®Google Scholar
• Fellenberg J, Kunz P, Sähr H, et al. Overexpression of inosine 5ʹ-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells. PLoS One. 2010;5(8):e12179.
   PubMed Web of Science ®Google Scholar
• Malek K, Boosalis MS, Waraska K, et al. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies. Leuk Res. 2004;28(11):1125–1136.
   PubMed Web of Science ®Google Scholar
• Golub D, Iyengar N, Dogra S, et al. Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics. Front Oncol. 2019;9:417.
   PubMed Web of Science ®Google Scholar
• Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, et al. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2017;60(9):1639–1647.
   PubMed Web of Science ®Google Scholar